Last reviewed · How we verify
Buprenorphine transdermal patch
Buprenorphine transdermal patch, marketed by Purdue Pharma LP, holds a significant position in the pain management segment. The key composition patent is set to expire in 2028, providing a strong barrier to generic competition until then. The primary risk lies in the potential for increased competition post-patent expiry.
At a glance
| Generic name | Buprenorphine transdermal patch |
|---|---|
| Also known as | Butrans™, Naltrexone Hydrochloride, Norspan transdermal patch, Sovenor transdermal patch, Butrans |
| Sponsor | Purdue Pharma LP |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (PHASE1, PHASE2)
- Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE) (PHASE3)
- Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery (PHASE4)
- An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders (NA)
- Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy (PHASE4)
- Transdermal Buprenorphine Patch for Laparoscopic Cholecystectomy (NA)
- Improved Pain Management in Knee Osteoarthritis-related Surgeries
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buprenorphine transdermal patch CI brief — competitive landscape report
- Buprenorphine transdermal patch updates RSS · CI watch RSS
- Purdue Pharma LP portfolio CI